GLPwatch
Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.
Curr Drug Saf · 2018
Last updated 2026-05-28A review of 25 studies on dulaglutide, a GLP-1 drug approved for type 2 diabetes, found it may help with weight loss, slow kidney damage, lower heart attack risk, and reduce blood pressure. However, the analysis also linked the drug to serious risks including infections like septicemia, certain cancers, heart disease, and pancreatic cancer.
AI summary of the abstract below.
| Journal | Curr Drug Saf, 2018 |
|---|---|
| Citations | 10 |
| Relative citation ratio | 0.45 |
| NIH percentile | 27 |
| Molecules | dulaglutide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction, Obesity |
Abstract
BACKGROUND: Recently, Food and Drug Administration (FDA) has approved Dulaglutide (GLP-1 analog) for the treatment of type 2 diabetes mellitus. However, regarding Adverse Drug Reactions (ADRs) of Dulaglutide in a large group of population, very less information is available. Thus, in the present investigation, we tried to find out the risk and benefit profile of Dulaglutide.
MATERIALS AND METHODS: The data related to risk and benefit profile of Dulaglutide has been extracted from various sources like Pub-Med, Regulatory Websites of various agencies, Clinical trial registry etc. from Sep 2014 (first approval) to Feb 2018. A total of 182 studies have been published from Sep 2014 to Feb 2018 regarding Dulaglutide. After inclusion and exclusion criteria, 25 studies have been selected for risk and benefit analysis.
RESULTS: The results of the current study have shown the various therapeutic benefits of Dulaglutide (reduces weight, decreases progression of nephropathy, reduces incidence of myocardial infarction, reduces blood pressure etc.) in the treatment of type 2 diabetes mellitus. However, emerging evidence has also indicated the various risks associated with Dulaglutide such as septicemia, malignant neoplasm, coronary artery disease and pancreatic cancer.
CONCLUSION: In conclusion, Marketing Authorization Holder (MAH) and Regulatory Authorities (RAs) should consider these safety issues in future.
Verbatim abstract via PubMed 29852875 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).